苏州宜联生物医药有限公司 MediLink Therapeutics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy 2024-10-08 08:00
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits 2024-09-14 01:00
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership 2024-05-27 08:00
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology 2024-01-02 22:00
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate 2023-10-12 19:00
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment 2023-09-23 18:29
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product 2022-04-12 20:55
MediLink Therapeutics closes US$70 million Series B financing 2022-03-14 20:50
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development 2021-03-01 19:50
1